Pharmacogenomics Market
Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel ( Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Technology ( DNA Sequencing, Polymerase Chain Reaction, Microarray, Mass Spectrometry and Electrophoresis), Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $16.66 BN |
|
Projected Year Value (2030) |
US $34.81 BN |
|
CAGR (2023 - 2030) |
11.1% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $16.66 billion in 2023 and is expected to reach $34.81 billion by 2030 growing at a CAGR of 11.1% during the forecast period. The study of developing drugs by analysing genetic variations in humans that affect an individual's response to a particular drug is known as pharmacogenomics. This approach is vital for precision medicine, offering personalised treatment plans based on genetic markers. It is essential to improving patient outcomes, reducing adverse drug reactions, enhancing medication efficacy, and providing more cost-effective healthcare.
According to data published by National Cancer Institute in September 2020, stated that an estimated 1,806,590 new cases of cancer will be diagnosed in the U.S. and 606,520 people will die from the disease in 2020.
Market Dynamics:
Driver:
Increasing adoption of personalized medicine
Personalised medicine is an approach that tailors medical treatments to an individual's genetic, genomic, and clinical characteristics. It aims to maximise treatment effectiveness, minimise side effects, and improve patient outcomes by customising healthcare interventions. As patients and healthcare providers become more aware of the potential benefits of pharmacogenomics, the demand for genetic testing and personalised treatment plans is on the rise. Furthermore, pharmaceutical companies are also investing in targeted therapies based on genomic data. This convergence of patient demand, clinical relevance, and industry innovation is propelling the growth of the pharmacogenomics market.
Restraint:
Cost barriers
Cost barriers pose a significant restraint on the Pharmacogenomics market. Genetic testing and pharmacogenomic services can be expensive, making them inaccessible to many patients and healthcare systems. The high costs of DNA sequencing, data analysis, and interpretation can limit the adoption of pharmacogenomics, especially in resource-constrained environments. This financial burden can result in unequal access to the benefits of personalised medicine, exacerbating healthcare disparities.
Opportunity:
Advancements in genetic testing technologies
Developments in genetic testing can spur growth by lowering the cost, increasing accessibility, and expanding the availability of testing. Genetic testing is getting easier to obtain, less expensive, and more accurate as technology advances. Furthermore, the process is made easier for patients and healthcare professionals by the creation of user-friendly at-home testing kits and mobile health applications. Moreover, these developments not only simplify genetic information availability for individuals but also make it easier to incorporate pharmacogenomic data into standard therapeutic procedures. Growing pharmacogenomics market share and wider adoption of personalised medicine are made possible by the increasing prevalence of genetic testing.
Threat:
Data privacy and security
Genetic information is highly sensitive, and the mishandling or unauthorised access to this data could lead to privacy breaches, identity theft, or discrimination. Patients may be hesitant to undergo genetic testing or share their data, fearing potential misuse. Furthermore, regulatory frameworks for safeguarding genetic information are continually evolving and can create compliance challenges for healthcare providers and pharmaceutical companies. Hence, it will lead to a decrease in market growth.
Covid-19 Impact
The COVID-19 pandemic has had a multifaceted impact on the market. On one hand, it accelerated the adoption of digital health, including telehealth and remote monitoring, which can complement pharmacogenomics by facilitating data sharing and patient consultations. The urgency of the pandemic also led to increased research and investment in healthcare and pharmaceuticals, potentially driving advancements in pharmacogenomics. However, there were negative effects as well. Many healthcare resources and research efforts were redirected toward COVID-19, potentially slowing the progress of pharmacogenomics projects. Clinical trials for pharmacogenomic therapies may have been delayed or disrupted due to lockdowns and safety concerns.
The DNA Sequencing segment is expected to be the largest during the forecast period
The DNA Sequencing segment is estimated to hold the largest share. DNA sequencing involves determining the precise order of DNA bases in an individual's genome. By analysing genetic variations, researchers and healthcare providers can identify specific genes and genetic markers relevant to drug response and disease susceptibility. This information enables the customization of medical treatments, ensuring the most effective and safe therapeutic options for patients. In addition, advances in DNA sequencing technologies, such as next-generation sequencing, have made it faster and more cost-effective to obtain genomic data, driving the growth of this segment and expanding the potential applications of pharmacogenomics in healthcare.
The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period
The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The healthcare facilities utilise pharmacogenomic testing to customise drug treatment plans, ensuring that medications are both effective and safe for individual patients. Pharmacogenomics can help clinicians identify the most suitable drug therapies and dosages, minimising adverse reactions and optimising patient outcomes. Furthermore, it aids in the selection of treatments for various medical conditions, from cancer to cardiovascular diseases. As the demand for personalised medicine grows, hospitals and clinics are essential in integrating pharmacogenomics into routine clinical practice, revolutionising healthcare by providing individualised, data-driven treatment plans.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a significant and rapidly growing market for pharmacogenomics. The region faces a rising burden of chronic diseases, including cancer, cardiovascular diseases, and diabetes, which has led to a growing demand for personalised medicine and pharmacogenomic solutions. Countries in the Asia-Pacific region, such as China, Japan, and South Korea, have made substantial investments in genomics research, leading to significant advancements in understanding genetic factors influencing drug responses and diseases.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period. North America boasts advanced healthcare systems, including well-established hospitals, research institutions, and pharmaceutical companies, providing a solid foundation for the growth of pharmacogenomics. Regulatory agencies, such as the FDA in the United States, have been proactive in recognising the importance of pharmacogenomics in drug development, approval, and labelling, which accelerates its adoption. Furthermore, North American pharmaceutical companies have heavily invested in pharmacogenomics, resulting in the development of numerous personalised therapies. The region is at the forefront of pharmacogenomic research, with substantial investments in genomic studies, clinical trials, and the development of targeted therapies.
Key players in the market
Some of the key players in the Pharmacogenomics Market include Novartis AG, Ferndale Pharma Group, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Lupin, NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boehringer Ingelheim International GmbH, Abbott, Bayer AG, Thermo Fisher Scientific, Inc., Admera Health and Agilent Technologies.
Key Developments:
In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2
In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
Distribution Channels Covered:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Technologies Covered:
• DNA Sequencing
• Polymerase Chain Reaction
• Microarray
• Mass Spectrometry
• Electrophoresis
Applications Covered:
• Drug Discovery
• Oncology
• Neurology
• Pain Management
• Cardiovascular diseases
• Psychiatry
• Infectious diseases
• Other Applications
End Users Covered:
• Hospitals & Clinics
• Research Institutions and Academic Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Pharmacogenomics Market, By Distribution Channel
5.1 Introduction
5.2 Hospital Pharmacy
5.3 Retail Pharmacy
5.4 Online Pharmacy
6 Global Pharmacogenomics Market, By Technology
6.1 Introduction
6.2 DNA Sequencing
6.3 Polymerase Chain Reaction
6.4 Microarray
6.5 Mass Spectrometry
6.6 Electrophoresis
7 Global Pharmacogenomics Market, By Application
7.1 Introduction
7.2 Drug Discovery
7.3 Oncology
7.4 Neurology
7.5 Pain Management
7.6 Cardiovascular diseases
7.7 Psychiatry
7.8 Infectious diseases
7.9 Other Applications
8 Global Pharmacogenomics Market, By End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research Institutions and Academic Institutes
8.4 Other End Users
9 Global Pharmacogenomics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Novartis AG
11.2 Ferndale Pharma Group, Inc.
11.3 Mylan N.V.
11.4 F. Hoffmann-La Roche Ltd
11.5 Takeda Pharmaceutical Company Limited
11.6 Pfizer Inc.
11.7 AstraZeneca
11.8 Merck & Co., Inc.
11.9 Eli Lilly and Company
11.10 Sun Pharmaceutical Industries Ltd.
11.11 Lupin
11.12 NATCO Pharma Limited
11.13 Teva Pharmaceutical Industries Ltd
11.14 AbbVie Inc.
11.15 Boehringer Ingelheim International GmbH
11.16 Abbott
11.17 Bayer AG
11.18 Thermo Fisher Scientific, Inc.
11.19 Admera Health
11.20 Agilent Technologies
List of Tables
1 Global Pharmacogenomics Market Outlook, By Region (2021-2030) ($MN)
2 Global Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
3 Global Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
4 Global Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
5 Global Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
6 Global Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
7 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
8 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
9 Global Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
10 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
11 Global Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
12 Global Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
13 Global Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
14 Global Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
15 Global Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
16 Global Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
17 Global Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
18 Global Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
19 Global Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
20 Global Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
21 Global Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
22 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
23 Global Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
24 Global Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
25 North America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
26 North America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
27 North America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
28 North America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
29 North America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
30 North America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
31 North America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
32 North America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
33 North America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
34 North America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
35 North America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
36 North America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
37 North America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
38 North America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
39 North America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
40 North America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
41 North America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
42 North America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
43 North America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
44 North America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
45 North America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
46 North America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
47 North America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
48 North America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
49 Europe Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
50 Europe Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
51 Europe Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
52 Europe Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
53 Europe Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
54 Europe Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
55 Europe Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
56 Europe Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
57 Europe Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
58 Europe Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
59 Europe Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
60 Europe Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
61 Europe Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
62 Europe Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
63 Europe Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
64 Europe Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
65 Europe Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
66 Europe Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
67 Europe Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
68 Europe Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
69 Europe Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
70 Europe Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
71 Europe Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
72 Europe Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
73 Asia Pacific Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
74 Asia Pacific Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
75 Asia Pacific Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
76 Asia Pacific Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
77 Asia Pacific Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
78 Asia Pacific Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
79 Asia Pacific Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
80 Asia Pacific Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
81 Asia Pacific Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
82 Asia Pacific Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
83 Asia Pacific Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
84 Asia Pacific Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
85 Asia Pacific Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
86 Asia Pacific Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
87 Asia Pacific Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
88 Asia Pacific Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
89 Asia Pacific Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
90 Asia Pacific Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
91 Asia Pacific Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
92 Asia Pacific Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
93 Asia Pacific Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
94 Asia Pacific Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
95 Asia Pacific Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
96 Asia Pacific Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
97 South America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
98 South America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
99 South America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
100 South America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
101 South America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
102 South America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
103 South America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
104 South America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
105 South America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
106 South America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
107 South America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
108 South America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
109 South America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
110 South America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
111 South America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
112 South America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
113 South America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
114 South America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
115 South America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
116 South America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
117 South America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
118 South America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
119 South America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
120 South America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
121 Middle East & Africa Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
122 Middle East & Africa Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
123 Middle East & Africa Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
124 Middle East & Africa Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
125 Middle East & Africa Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
126 Middle East & Africa Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
127 Middle East & Africa Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
128 Middle East & Africa Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
129 Middle East & Africa Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
130 Middle East & Africa Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
131 Middle East & Africa Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
132 Middle East & Africa Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
133 Middle East & Africa Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
134 Middle East & Africa Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
135 Middle East & Africa Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
136 Middle East & Africa Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
137 Middle East & Africa Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
138 Middle East & Africa Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
139 Middle East & Africa Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
140 Middle East & Africa Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
141 Middle East & Africa Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
142 Middle East & Africa Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
143 Middle East & Africa Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
144 Middle East & Africa Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
